TScan Therapeutics (TCRX) News Today $0.20 -0.01 (-6.01%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$0.20 0.00 (-0.59%) As of 10/23/2026 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings TScan Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Comparing TScan Therapeutics (NASDAQ:TCRX) and Arbutus Biopharma (NASDAQ:ABUS)October 20, 2026 | americanbankingnews.comTScan Therapeutics (NASDAQ:TCRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical ReviewOctober 17, 2026 | americanbankingnews.comTScan Therapeutics Announces Board and Governance ChangesOctober 16, 2026 | tipranks.comFinancial Analysis: argenex (NASDAQ:ARGX) vs. TScan Therapeutics (NASDAQ:TCRX)October 15, 2026 | americanbankingnews.comTScan Therapeutics consensus price target decreased by 55.56% to $2.72September 16, 2026 | msn.comWedbush downgrades TScan Therapeutics (TCRX) to neutral from outperformSeptember 3, 2026 | msn.comTScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%September 2, 2026 | rttnews.comTScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor programSeptember 2, 2026 | msn.comTScan Reorganizes Pipeline Priorities, Implements Workforce ReductionSeptember 2, 2026 | benzinga.comTScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid TumorsSeptember 2, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)August 13, 2026 | theglobeandmail.comTScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 ResultsAugust 12, 2026 | quiverquant.comQTScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 12, 2026 | globenewswire.comTScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme MalignanciesJuly 29, 2026 | globenewswire.comTScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 24, 2026 | globenewswire.comTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...June 23, 2026 | markets.businessinsider.comTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationJune 22, 2026 | globenewswire.comCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic MalignanciesJune 3, 2026 | businesswire.comTScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net LossJune 2, 2026 | insidermonkey.comTScan Therapeutics Expands Authorized Shares After Stockholder VoteMay 22, 2026 | tipranks.comTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingApril 27, 2026 | globenewswire.comTScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | globenewswire.comTScan Therapeutics Consolidates Finance Leadership After Officer ResignationApril 2, 2026 | tipranks.comTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 4, 2026 | globenewswire.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102 ...February 26, 2026 | markets.businessinsider.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03February 26, 2026 | globenewswire.comTScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceFebruary 25, 2026 | globenewswire.comTScan Therapeutics (NASDAQ:TCRX) Major Shareholder Acquires $67,950.00 in StockDecember 24, 2025 | insidertrades.comTScan Therapeutics announces updated data from ALLOHA Phase 1 trialDecember 7, 2025 | msn.comTScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and ExpositionDecember 7, 2025 | markets.businessinsider.comTScan Therapeutics Announces Positive Updated Data from the ALLOHAâ„¢ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and ExpositionDecember 6, 2025 | globenewswire.comTScan Therapeutics Reports Promising Two-Year Relapse-Free Survival Data for TSC-101 in Phase 1 Trial for Hematologic MalignanciesDecember 6, 2025 | quiverquant.comQTScan Therapeutics (TCRX) price target increased by 10.53% to 7.14December 6, 2025 | msn.comTScan Therapeutics to Host Virtual KOL Event on ALLOHA™ Phase 1 Trial Data and Market OpportunitiesDecember 3, 2025 | quiverquant.comQTScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market OpportunitiesDecember 3, 2025 | globenewswire.comTScan Therapeutics Approves Key Employee Retention ProgramNovember 27, 2025 | msn.comTScan Therapeutics (TCRX) Price Target Decreased by 25.49% to 6.46November 17, 2025 | msn.comTScan Therapeutics downgraded to Equal Weight from Overweight at Morgan StanleyNovember 14, 2025 | msn.comHC Wainwright & Co. Maintains TScan Therapeutics (TCRX) Buy RecommendationNovember 14, 2025 | msn.comTScan Therapeutics Reports Increased Revenue Amid Rising LossesNovember 13, 2025 | msn.comTScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateNovember 12, 2025 | globenewswire.comBTIG Downgrades TScan Therapeutics (TCRX)November 5, 2025 | msn.comBarclays Reaffirms Their Buy Rating on TScan Therapeutics (TCRX)November 5, 2025 | theglobeandmail.comTScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceNovember 5, 2025 | globenewswire.comNeedham Maintains TScan Therapeutics (TCRX) Buy RecommendationNovember 4, 2025 | msn.comTScan Therapeutics Shifts Focus to Hematologic MalignanciesNovember 3, 2025 | msn.comTScan Therapeutics to reduce workforce by 30%November 3, 2025 | msn.comTScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027November 3, 2025 | globenewswire.comTScan Therapeutics’ Innovative Cancer Study: A Potential Game-Changer for Solid TumorsOctober 27, 2025 | tipranks.com TScan Therapeutics Media Mentions By Week TScan Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TCRX News Sentiment▼-0.330.47▲Average Healthcare News Sentiment TScan Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TCRX Articles This Week▼12▲TCRX Articles Average Week TScan Therapeutics Trends on MarketBeatThis week vs. last weekNew Followers1Searches1Page Views1,276-18% Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Gossamer Bio News Today Xilio Therapeutics News Today Pliant Therapeutics News Today Connect Biopharma News Today Caribou Biosciences News Today iBio News Today Boundless Bio News Today Biomea Fusion News Today Yarrow Bioscience News Today Gain Therapeutics News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for TScan Therapeutics dated 10/16/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
